title: [Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin].
abstract: OBJECTIVE
  To assess the effect of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin.
  
  
  METHODS
  Recombinant eukaryotic expression vector pcDNA3 containing full-length human wild-type p53 cDNA was introduced by lipofectamine-mediated gene transfection into SKOV-3 cultured cells which were acted on by cisplatin of different concentrations. The chemotherapy sensitivity of tumor cells with different-status p53 was observed.
  
  
  RESULTS
  The inhibitive rate of formation of clones after p53 cDNA transfection was 56.4% compared with the untransfected one. The formation of clones decreased by 76.2% and 84.1% respectively after being acted on by 0.5 ug/ml cisplatin for 24 hours and 48 hours respectively. The formation of clones decreased by 89.5% and 93.7% respectively after being acted on by 1 ug/ml cisplatin for 24 hours and 48 hours respectively. After the introduction of p53 cDNA, the S phase and the ratio of G(2)/M phase of tumor cells decreased, and the ratio of G(1)/G(0) phase increased. The introduction of p53 gene into cells led to cell cycle arrest in G(1) phase.
  
  
  CONCLUSIONS
  The exogenous introduction of wild-type p53 cDNA into ovarian cancer SKOV-3 cells increased the chemotherapy sensitivity to cisplatin.
authors.affiliation: Department of Obstetrics and Gynecology, the Second Hospital, China Medical University, Shenyang, Liaoning, 110004 P. R. China. peiling@ihw.com.cn
authors.forename: Zhen
authors.initials: Z
authors.lastname: Jin
authors.forename: Ting
authors.initials: T
authors.lastname: Guan
authors.forename: Shourou
authors.initials: S
authors.lastname: Li
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D015152:Blotting, Northern; D015153:Blotting, Western; D002453:Cell Cycle / Q000502:physiology; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D002945:Cisplatin / Q000494:pharmacology*; D018076:DNA, Complementary / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D010957:Plasmids / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013997:Time Factors; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism / Q000502:physiology*
chemical_list: D000970:Antineoplastic Agents; D018076:DNA, Complementary; D012333:RNA, Messenger; D016159:Tumor Suppressor Protein p53; D002945:Cisplatin